Use of pulmonary surfactants in lung transplantation and methods thereof
The present invention concerns a method of treating an advanced lung disease in a patient in need thereof by lung transplantation.
1. A method of treating an advanced lung disease selected from the group consisting of advanced chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), cystic fibrosis (CF), emphysema due to alpha-1 antitrypsin deficiency, and idiopathic pulmonary arterial hypertension (IPAH) in a patient in need thereof by lung transplantation, said method comprising:
(i) withdrawing a lung with trachea to be implanted from a donor and dissecting it on a backtable;
(ii) administering a therapeutically effective amount of an aqueous suspension of pulmonary surfactant poractant alfa having a concentration of 80 mg/ml based on the total volume of said aqueous suspension directly into the trachea on said back table after withdrawal of said lung;
(iii) preserving said lung until implantation; and
(iv) transplanting said lung into said patient,
wherein said preserving said lung (iii) is carried out by applying a hypothermic (cold) static lung preservation technique.
2. A method according to claim 1 , wherein said cold preservation technique is performed at a temperature of 4° C.
3. A method according to claim 1 , wherein said poractant alfa is administered in an amount of 10 to 200 mg/kg of body weight of said donor.
4. A method according to claim 1 , wherein said poractant alfa is administered in an amount of 25 to 80 mg/kg of body weight of said donor.
5. A method according to claim 1 , wherein said poractant alfa is administered in an amount of 30 mg/kg of body weight of said donor.
6. A method according to claim 1 , wherein said poractant alfa is administered into the trachea with a bronchoscope.
7. A method according to claim 1 , wherein said poractant alfa is administered into the trachea without a bronchoscope.
8. A method according to claim 1 , wherein said advanced lung disease is advanced chronic obstructive pulmonary disease (COPD).
9. A method according to claim 1 , wherein said advanced lung disease is idiopathic pulmonary fibrosis (IPF).
10. A method according to claim 1 , wherein said advanced lung disease is cystic fibrosis (CF).
11. A method according to claim 1 , wherein said advanced lung disease is emphysema due to alpha-1 antitrypsin deficiency.
12. A method according to claim 1 , wherein said advanced lung disease is idiopathic pulmonary arterial hypertension (IPAH).
13. A method according to claim 1 , wherein said cold preservation technique is performed at a temperature of 4° C. or 10° C.
14. A method of treating an advanced lung disease selected from the group consisting of advanced chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), cystic fibrosis (CF), emphysema due to alpha-1 antitrypsin deficiency, and idiopathic pulmonary arterial hypertension (IPAH) in a patient in need thereof by lung transplantation, said method comprising:
(i) withdrawing a lung with trachea to be implanted from a donor and dissecting it on a backtable;
(ii) administering a therapeutically effective amount of an aqueous suspension of pulmonary surfactant poractant alfa having a concentration of 80 mg/ml based on the total volume of said aqueous suspension directly into the trachea on said back table after withdrawal of said lung;
(iii) preserving said lung until implantation; and
(iv) transplanting said lung into said patient,
wherein said preserving said lung (iii) is carried out by applying a hypothermic (cold) static lung preservation technique without continuous perfusion and ventilation.
15. A method according to claim 14 , wherein said cold preservation technique is performed at a temperature of 4° C.
16. A method according to claim 14 , wherein said poractant alfa is administered in an amount of 10 to 200 mg/kg of body weight of said donor.
17. A method according to claim 14 , wherein said poractant alfa is administered in an amount of 25 to 80 mg/kg of body weight of said donor.
18. A method according to claim 14 , wherein said poractant alfa is administered in an amount of 30 mg/kg of body weight of said donor.
19. A method according to claim 14 , wherein said poractant alfa is administered into the trachea with a bronchoscope.
20. A method according to claim 14 , wherein said poractant alfa is administered into the trachea without a bronchoscope.
21. A method according to claim 14 , wherein said advanced lung disease is advanced chronic obstructive pulmonary disease (COPD).
22. A method according to claim 14 , wherein said advanced lung disease is idiopathic pulmonary fibrosis (IPF).
23. A method according to claim 14 , wherein said advanced lung disease is cystic fibrosis (CF).
24. A method according to claim 14 , wherein said advanced lung disease is emphysema due to alpha-1 antitrypsin deficiency.
25. A method according to claim 14 , wherein said advanced lung disease is idiopathic pulmonary arterial hypertension (IPAH).
26. A method according to claim 14 , wherein said cold preservation technique is performed at a temperature of 4° C. or 10° C.